Sheena Marin Thomas, Geetha K , Vijayakumar.A, Rajasekaran.A
Objective: To obtain data on efficacy and safety of Acarbose combination therapy during daily life treatment. Methods- It’s a prospective study done for a period of 7 months in a south Indian hospital. Out of 74 Type II diabetic patients 40 patients were on Acarbose therapy and 34 patients were in another group taking oral hypoglycemics alone. After a period of three months in the Acarbose group 35 patients came for review and in the other group 26 patients came for review. The reduction in blood glucose profile in both groups were done. Based on body mass index (BMI) the patients were classified as obese and non obese and the significant reduction in post prandial blood glucose level (PPBS) and glycosylated hemoglobin (HbA1C) in each group were determined. Results- Among the study population 42 (56.7%) were male and 59 (43.2%) were female. The different doses of Acarbose prescribed were 25mg (48.64%), 50mg (37.83%) and 100mg (13.51%). The percentage reduction in blood glucose values in Acarbose group was found to be higher than oral hypoglycemics alone. The p value of PPBS and HbA1C in Acarbose group was found to be (p=0.002) and (p=0.043). Based on BMI they were classified as 27 (77.14) obese and 8 (22.8) as non obese. The p value of PPBS and HbA1C was highly significant in obese patients (p=0.0006) and (p<0.0001). Conclusion- Acarbose therapy was efficacious and well tolerated in daily life in patients with type II diabetes mellitus.
